Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Conflicts of interest

Doctors who accept industry lunches prescribe more promoted drugs

Doctors who accept free meals from the pharmaceutical industry have higher prescribing rates for the branded drugs the manufacturers promote, according to research published in JAMA Internal Medicine[1] (online, 20 June 2016).

Researchers wanted to discover whether there was a link between the number of free meals a physician accepted and their prescribing of promoted drugs. They analysed the Medicare health insurance prescribing data from the United States for individual physicians and data from the federal open payments programme — a system that reveals payments made to physicians from drug companies — between 1 August and 31 December 2013.

The researchers focused on four groups of drugs — statins; cardioselective β-blockers; angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs); and selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs).

They looked at data concerning 279,669 physicians and identified 63,524 payments associated with the most prescribed branded drug in each class (rosuvastatin [Crestor], nebivolol [Bystolic, branded as Nebilet in Europe], olmesartan [Benicar, branded as Olmetec in Europe] and desvenlafaxine [Pristiq], respectively). Some 95% of payments were for industry-sponsored meals with an average cost of less than US$20.

Physicians who received a single meal promoting the drug of interest had higher rates of prescribing rosuvastatin over other statins (adjusted odds ratio [OR] 1.18; 95% confidence interval [CI] 1.17–1.18); higher rates of prescribing nebivolol over other β-blockers (OR 1.70; 95% CI 1.69–1.72); olmesartan over other ACE inhibitors and ARBs (OR 1.52; 95% CI 1.51–1.53); and desvenlafaxine over other SSRIs and SNRIs (OR 2.18; 95% CI 2.13–2.23).

Accepting additional meals and meals costing more than US$20 was associated with higher relative prescribing rates, the researchers found. However, they warn that the findings represent an association, not a cause-and-effect relationship.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20201338

Readers' comments (1)

  • Bob Dunkley

    No s**t Sherlock, as they say. Well, who would've thought it!! I had to look where this research came from. I was surprised when I saw it was JAMA, Internal Medicine, and not the pages of Viz.
    Bob Dunkley

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons is the definitive reference source of analytical data for drugs and poisons.

    £535.00Buy now
  • Injectable Drugs Guide

    Injectable Drugs Guide

    A user friendly, single point of reference for healthcare professionals in the safe and effective administration of injectable medicines.

    £54.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Doctor writing a prescription

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.